IL208039A - Oxytocin analogs, their pharmaceutical compositions and their use in the preparation of a drug - Google Patents

Oxytocin analogs, their pharmaceutical compositions and their use in the preparation of a drug

Info

Publication number
IL208039A
IL208039A IL208039A IL20803910A IL208039A IL 208039 A IL208039 A IL 208039A IL 208039 A IL208039 A IL 208039A IL 20803910 A IL20803910 A IL 20803910A IL 208039 A IL208039 A IL 208039A
Authority
IL
Israel
Prior art keywords
medicament
manufacture
same
pharmaceutical compositions
oxytocin analogues
Prior art date
Application number
IL208039A
Other languages
English (en)
Hebrew (he)
Other versions
IL208039A0 (en
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39722695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL208039(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of IL208039A0 publication Critical patent/IL208039A0/en
Publication of IL208039A publication Critical patent/IL208039A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
IL208039A 2008-03-31 2010-09-07 Oxytocin analogs, their pharmaceutical compositions and their use in the preparation of a drug IL208039A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4097308P 2008-03-31 2008-03-31
EP08251739 2008-05-19
PCT/IB2009/005351 WO2009122285A1 (en) 2008-03-31 2009-03-30 Oxitocin analogues

Publications (2)

Publication Number Publication Date
IL208039A0 IL208039A0 (en) 2010-12-30
IL208039A true IL208039A (en) 2016-03-31

Family

ID=39722695

Family Applications (1)

Application Number Title Priority Date Filing Date
IL208039A IL208039A (en) 2008-03-31 2010-09-07 Oxytocin analogs, their pharmaceutical compositions and their use in the preparation of a drug

Country Status (20)

Country Link
US (1) US8673841B2 (enExample)
EP (2) EP2260053B1 (enExample)
JP (1) JP5539310B2 (enExample)
KR (1) KR101558404B1 (enExample)
CN (1) CN101983205B (enExample)
AU (1) AU2009233429B2 (enExample)
BR (1) BRPI0910345B1 (enExample)
CA (1) CA2718148C (enExample)
DK (1) DK2260053T3 (enExample)
ES (1) ES2488992T3 (enExample)
HR (1) HRP20140716T1 (enExample)
IL (1) IL208039A (enExample)
MX (1) MX2010010743A (enExample)
NZ (1) NZ587817A (enExample)
PL (1) PL2260053T3 (enExample)
PT (1) PT2260053E (enExample)
RU (1) RU2496788C2 (enExample)
SI (1) SI2260053T1 (enExample)
WO (1) WO2009122285A1 (enExample)
ZA (1) ZA201006733B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853158B2 (en) 2010-05-25 2014-10-07 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods for the treatment of a feeding disorder with onset during neonate development using an agonist of the oxytocin receptor
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
NZ708175A (en) 2012-12-21 2020-06-26 Hoffmann La Roche Peptides as oxytocin agonists
CA2949173A1 (en) 2014-06-03 2015-12-10 Caterina Bissantz Peptides as oxytocin agonists
CR20160562A (es) * 2014-06-06 2017-01-06 Hoffmann La Roche Péptidos como agonistas de la oxitocina
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
RS65144B1 (sr) 2014-09-19 2024-02-29 Ferring Bv Postupak za lečenje prader-vilijevog sindroma
CN106084015B (zh) * 2016-08-25 2020-01-31 成都圣诺生物制药有限公司 一种合成卡贝缩宫素的方法
US20190135859A1 (en) 2017-08-11 2019-05-09 Ferring B.V. Method of manufacturing a pharmaceutical composition
AU2018312956B2 (en) * 2017-08-11 2022-03-10 Ferring B.V. Method of manufacturing a pharmaceutical composition
CN107628975B (zh) * 2017-09-17 2019-10-29 贵州医科大学 赖氨酸衍生物类组蛋白去乙酰化酶抑制剂及其合成和应用
EP3852724A4 (en) 2018-09-20 2022-07-06 Levo Therapeutics, Inc. CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE
US20200093884A1 (en) 2018-09-20 2020-03-26 Mark C. Manning Stable intranasal formulations of carbetocin
WO2020137880A1 (ja) * 2018-12-27 2020-07-02 国立大学法人北海道大学 オキシトシン誘導体及びその使用
WO2021089554A1 (en) 2019-11-04 2021-05-14 Ferring B.V. Intranasal administration of merotocin for improving lactation
WO2022026463A1 (en) * 2020-07-27 2022-02-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Oxytocin analogues and methods for using the same
WO2022200568A1 (en) 2021-03-26 2022-09-29 Ot4B Treatment of dysphagia
WO2024044633A2 (en) * 2022-08-23 2024-02-29 Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) Oxytocin derivatives and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
DK1480998T3 (da) * 2002-02-27 2007-03-26 Ferring Bv Mellemprodukter og fremgangsmåder til fremstilling af heptapeptidoxytocinanaloger

Also Published As

Publication number Publication date
DK2260053T3 (da) 2014-06-23
JP5539310B2 (ja) 2014-07-02
WO2009122285A8 (en) 2009-12-10
CN101983205B (zh) 2015-08-19
CA2718148A1 (en) 2009-10-08
US8673841B2 (en) 2014-03-18
HRP20140716T1 (hr) 2014-08-29
EP2260053A1 (en) 2010-12-15
PL2260053T3 (pl) 2014-11-28
BRPI0910345A2 (pt) 2015-10-06
EP2626364A1 (en) 2013-08-14
WO2009122285A1 (en) 2009-10-08
RU2010139634A (ru) 2012-05-10
SI2260053T1 (sl) 2014-08-29
KR101558404B1 (ko) 2015-10-08
KR20110005705A (ko) 2011-01-18
EP2260053B1 (en) 2014-05-14
RU2496788C2 (ru) 2013-10-27
BRPI0910345B1 (pt) 2021-08-17
AU2009233429B2 (en) 2014-02-13
CA2718148C (en) 2017-11-07
HK1146064A1 (en) 2011-05-13
US20110044905A1 (en) 2011-02-24
CN101983205A (zh) 2011-03-02
AU2009233429A1 (en) 2009-10-08
ZA201006733B (en) 2011-06-29
ES2488992T3 (es) 2014-09-01
IL208039A0 (en) 2010-12-30
NZ587817A (en) 2012-05-25
PT2260053E (pt) 2014-08-29
JP2011516460A (ja) 2011-05-26
MX2010010743A (es) 2010-11-04

Similar Documents

Publication Publication Date Title
IL275854A (en) Pharmaceutical composition and its administration
IL214309A (en) Preserved pyridines, pharmaceuticals containing them and their use in the preparation of medicines
IL206952A (en) History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines
IL222268A (en) Preserved pyrollo-pyridines, containing pharmaceutical preparations, combined preparations containing them and their use in the preparation of medicines
IL213517A (en) Sulfonamide derivatives, pharmaceuticals containing them and their use in the preparation of drugs
IL212605A (en) Pyrimidine-4-carboxamide cycles and their use as drugs
IL212573A (en) Aryl Methyl Benzokinazulinone Compounds
IL213019A (en) Derivatives 1-Azo-3-Terroyl-Azoline, Pharmaceutical Preparations Containing and Using Them
IL256921A (en) Pyrazolopyrimidines, pharmaceutical preparations containing them and their use
IL250740A0 (en) Piperazine-2,5-dione derivatives, pharmaceutical preparations containing them and their use for the preparation of medicines
IL194699A (en) Tetrahydropridridines, preparations containing them and uses in the preparation of drugs
IL217572A (en) 3,1-Propanedisulfonic Acids
IL213622A (en) Benzamide compounds are being used and their use in making a drug
IL216006A (en) Processed aromatic compounds, pharmaceutical preparations including them and their use in the manufacture of pharmaceuticals
IL199835A (en) Acid-activated antimicrobial peptides, their pharmaceutical preparations, and their use in drug preparation
IL216405A (en) Pharmaceutical preparation containing melphalan and cyclodextrin derivative and used for drug preparation
IL216254A (en) Compounds, pharmaceutical compositions and their uses
IL197609A (en) Protease-resistant insulin analogues, pharmaceuticals containing them, their use in drug preparation and a nucleic acid sequence encoding these analogs
ZA201100830B (en) Novel benzamides,production thereof,and use thereof as medicaments
IL209867A (en) Cyclic peptides, pharmaceutical preparations containing them and their use as drugs
IL211946A (en) Annotated (2-Hydroxy-2-Phenyl-1-Pyrrolidine-1-Illmethyl-Ethyl) -Carbamic Acid Phenyl Ester
IL199362A (en) Pyridopyrimidine Compounds, Pharmaceuticals, Compounds for Use as a Drug, and Compounds for Manufacture @ Drug
IL233282A (en) Crystalline Forms of 5- (2,6-Di-4-Morpholinyl-4-Pyrimidinyl) -4-Trifluoromethylpyridine-2-Amine Monohydrochloride
GB2443336B (en) Spiruchostatin analogues and their medicinal use
EP2261221A4 (en) EPOTHILONE ANALOGUES, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR USE AND PREPARATIONS

Legal Events

Date Code Title Description
FF Patent granted
KB20 Patent renewed for 20 years